MBX Biosciences’ experimental once-weekly therapy canvuparatide achieved primary endpoints in a phase 2 study treating chronic hypoparathyroidism, a rare hormone disorder. While statistically significant, the efficacy was narrower than expected given a high placebo response. Plans are underway to advance to phase 3 testing next year. The data positions MBX to compete with an approved therapy, contributing to rare endocrine disease treatment options.